Randomization
Block randomization (block length of four, SAS 9.4 software) was used for the analysis, with participants assigned to either the Socazolimab + TP or Placebo + TP treatment groups. Identical packages of socazolimab/placebo were prepared and numbered by the sponsor, and the relevant drug package was randomly assigned to individuals within the appropriate groups in a 1:1 ratio (in accordance with the SAS 9.4 PROC PLAN procedure). All clinical staff involved in drug allocation were blinded to the study, as were the sponsors, investigators, patients, clinical contract research organizations, and independent review committees. Patient randomization and assignment of clinical trial drugs followed Interactive Web Response System-Balance (Medidata Solutions) protocols. Preparation and administration of nab-paclitaxel and cisplatin were conducted in accordance with the manufacturers’ instructions.